Stay updated on Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe header now shows Revision: v3.5.0, replacing Revision: v3.4.3.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3. There are no visible changes to study details or outcomes.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no clinical content, eligibility criteria, results, or critical page data were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. This appears to be a metadata update and does not affect core content or study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedAdded: Show glossary option, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4; no page content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.